Contract Research Organizations Are Seeking Transformation in the Pharmaceutical Value Chain

被引：2

作者：

Huang, Jianan ^{[1
]}

机构：

[1] Zhejiang Univ, Coll Pharmaceut Sci, Hangzhou ZJ571, Zhejiang, Peoples R China

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2019年 / 10卷 / 05期

关键词：

Contract Research Organization; supply chain disruption; decision-tree model; risk-sharing; value chain;

D O I：

10.1021/acsmedchemlett.9b00046

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Since the beginning, Contract Research Organizations (CROs) have always faced two core challenges: low profit margin and limited market capitalization. Nowadays, the CRO industry is experiencing a supply chain disruption, driving it to chase the upstream part of the pharmaceutical value chain. A 3P (past, present, prospect) decision-tree model is developed, revealing the future of the CRO industry may be a CRO-Venture model. Perspectives on the potential transformation of CRO industry will contribute to the real-world practice and innovation of this business model.

引用

页码：684 / 686

页数：5

共 6 条

[1] THE INTRA-ALLIANCE DIVISION OF VALUE CREATED THROUGH COLLABORATION
Adegbesan, J. Adetunji
Higgins, Matthew J.
[J]. STRATEGIC MANAGEMENT JOURNAL, 2011, 32 (02) : 187 - 211
[2] [Anonymous], 2008, INNOVATORS PRESCRIPT
[3] Champion D, 2001, HARVARD BUS REV, V79, P108
[4] The changing role of CROs: The evolution of strategic out-sourcing
Crouch, TJ
[J]. CLINICAL RESEARCH AND REGULATORY AFFAIRS, 1997, 14 (3-4) : 205 - 220
[5] Guiding principles of value creation through collaborative innovation in pharmaceutical research
Schweizer, Liang
He, Jeff
[J]. DRUG DISCOVERY TODAY, 2018, 23 (02) : 213 - 218
[6] Drug Discovery: Collaborations between Contract Research Organizations and the Pharmaceutical Industry
Steadman, Victoria A.
[J]. ACS MEDICINAL CHEMISTRY LETTERS, 2018, 9 (07): : 581 - 583

← 1 →